Operates the world's first frozen bone-marrow bank for transplants; $158M raised, $300M valuation per Forbes NBDS 2026.
Biotech
Current Valuation
$300M
as of 2026-07
PRIVATE
QL Price
$300M
0% vs last round
QuantLogix's current estimate for Ossium Health, published 2026-10-14 — in line with the last disclosed round of $300M (2026-07).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$300M
2026-07
weight 0.82
How this price has held up
No round has priced for Ossium Health since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-14 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Ossium Health, 2026-10-14 (3240b36c197ecdda).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Ossium Health going public?
No. Ossium Health is private and has not filed to go public. There is no S-1 on file.
What is Ossium Health's valuation in 2026?
Ossium Health is valued at $300M as of Jul 2026. That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Ossium Health filed an S-1?
No public S-1 is on file for Ossium Health.
How much has Ossium Health raised?
Ossium Health has raised $158M in total.
Is Ossium Health publicly traded — can you buy Ossium Health stock?
No. Ossium Health is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Ossium Health on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Name-verified against lead sponsor "Ossium Health, Inc." on ClinicalTrials.gov as of 2026-10-14. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▼ Hiring downtrend
-25% vs 2026-08
Open roles
6
via greenhouse
Product-build share
33%
engineering, research, product, design
Trajectory
tightening
balanced build + GTM — 33% builders vs 67% go-to-market/G&A — scaling both sides.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Clinical Production Operator I/II, HPC MarrowMedical Science Liaison (Western US)Chief Financial OfficerCustomer Support SpecialistProduction Supervisor, HPC, MarrowTissue Recovery Specialist (Contract) - Northern OR Southern Indiana
Counted from Ossium Health's live job board as of 2026-09-28; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechHealthcare
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-07. Refreshed quarterly.